Hixon Zuercher LLC increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,275 shares of the company’s stock after purchasing an additional 339 shares during the quarter. Johnson & Johnson accounts for 3.9% of Hixon Zuercher LLC’s holdings, making the stock its 4th biggest position. Hixon Zuercher LLC’s holdings in Johnson & Johnson were worth $6,084,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Family CFO Inc bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $26,000. RE Dickinson Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after acquiring an additional 98 shares during the period. Advanced Research Investment Solutions LLC raised its holdings in shares of Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after acquiring an additional 120 shares during the period. Professional Financial Advisors LLC raised its holdings in shares of Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after acquiring an additional 68 shares during the period. Finally, Joseph P. Lucia & Associates LLC acquired a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $38,000. 68.59% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Performance
JNJ stock opened at $166.18 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $436.92 billion, a price-to-earnings ratio of 24.19, a P/E/G ratio of 2.95 and a beta of 0.61. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a 50 day moving average of $168.06 and a two-hundred day moving average of $174.12.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.72%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is 65.79%.
Johnson & Johnson announced that its board has initiated a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. SVB Leerink cut their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Citigroup cut their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. UBS Group dropped their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Finally, Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Monday, September 12th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.78.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.